A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)
- Conditions
- SARS-CoV-2COVID-19
- Interventions
- Other: blood sample
- Registration Number
- NCT04347850
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
SARV-CoV-2 infection was considered pandemic on March 11, 2020. The SARV-CoV-2 epidemic affected France from the beginning of March, spreading in particular from a 4-day large evangelical meeting of 2500 people on February 17 in the city of Mulhouse (North East of France). The Montpellier University Hospital has set up a clinical pathway for people suspected of being infected with SARV-CoV-2 because of signs compatible with pneumonia (screening criteria in France during the study period). This includes an emergency department, an infectious disease department dedicated to the surveillance of infected people requiring hospital treatment, and an intensive care unit for the most severe cases. The diagnosis of infection with SARV-CoV-2 was confirmed in approximately 20% of people initially referred in this special care system.
The main objective of this cohorte is the collection of clinical data and biological samples from care for non-interventional research on the patients with a possible or confirmed SARS-CoV -2 infection, from diagnosis to long-term follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patient with Covid-19 confirmed (severe form) blood sample Covid-19 confirmed : severe form Patient with Covid-19 confirmed (middle form) blood sample Covid-19 confirmed: middle form Patient with Covid-19 not confirmed blood sample Covid-19 not confirmed
- Primary Outcome Measures
Name Time Method Number of confirmed COVID-19 1 day Number of confirmed COVID-19
- Secondary Outcome Measures
Name Time Method Description of trans pulmonary motor pressure in COVID 19+ patients in severe stage in intensive care 1 day TRANSPULMONARY-COVID19 substudy
Characterization in clinical proteomics of the SARS-CoV-2 spike protein 1 day ProteoCOVID substudy
Identification and validation of predictive biomarkers of a poorer respiratory evolution associated with positive testing for SARS-CoV-2 infection 1 day CORO-TRI substudy
Diagnosis of endocrine dysfunctions in Covid-19 1 day Dyhor-19 substudy
Assessment of Extra Vascular Lung Water and Pulmonary Permeability by transpulmonary thermodilution in critically ill patients with Coronavirus Disease 2019 pneumonia under invasive mechanical ventilation 1 day PiCCOVID substudy
Acral cutaneous thrombotic vasculopathy and Covid-19 infection : search for acquired thrombophilia and interferon-alpha signature 1 day Vasculopathy substudy
Evaluation of a COVID-19 screening strategy combining chest low dose CT and RT-PCR test for patients admitted for surgical or interventional procedures during the COVID 19 outbreak 1 day COVID-Scan study
Evaluate the morbidity and mortality and these risk factors linked to Covid-19 in the congenital heart disease population in France 1 day COVID-CHD substudy
Evaluate diagnostic tests for olfactory function in relation to the RT-PCR procedure 1 day Olfa-covid substudy
Immuno-monitoring of COVID-19 positive patients 1 day CytoCOVID substudy
Number of severe COVID-19 1 day Number of severe COVID-19
Identify the characteristics of physiotherapy care for patients with COVID-19 in intensive care 1 day Physio-Covid substudy
To assess the accuracy and prognostic performance of clinical and biological parameters measured on admission to the emergency department to stratify patients suspected of COVID-19 1 day Covida substudy
describe the occurrence of Covid19 infection in patients with systemic lupus erythematosus treated with hydroxychloroquine over the long term 1 day Lupus substudy
Trial Locations
- Locations (1)
Uh Montpellier
🇫🇷Montpellier, France